Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-CD19 CAR-NK cells (Shahid Beheshti University of Medical Sciences)
- Development stage
- Unknown
- Lead developer
- Shahid Beheshti University of Medical Sciences
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
anti-CD19 CAR-NK cells (Shahid Beheshti University of Medical Sciences) is an investigational cell therapy consisting of natural killer (NK) cells genetically modified to express a chimeric antigen receptor (CAR) targeting the CD19 antigen. Developed by Shahid Beheshti University of Medical Sciences, this therapy is primarily being evaluated for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). The CAR-NK cells are designed to recognize and eliminate CD19-positive malignant B cells while potentially offering advantages over CAR-T cell therapies, such as a reduced risk of cytokine release syndrome (CRS) and graft-versus-host disease (GvHD), as well as the potential for off-the-shelf application from allogeneic sources.
- Other names
- anti-CD19 CAR-NK cellsanti-CD-19 CAR-NK cellsanti-CD 19 CAR-NK cellsanti CD19 CAR NK cells
02
Targets
Beyond the preview
Go deeper on anti-CD19 CAR-NK cells (Shahid Beheshti University of Medical Sciences).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-CD19 CAR-NK cells (Shahid Beheshti University of Medical Sciences).